Angiotensin-converting-enzyme inhibitors and angiotensin II re-ceptor blockers for COVID-19: A living systematic review of randomized clinical trials

Vista sencilla de ítem
dc.contributor.authorMeza, Nicolás
dc.contributor.authorPérez-Bracchiglione, Javier
dc.contributor.authorPérez, Ignacio
dc.contributor.authorCarvajal, Cristhian
dc.contributor.authorOrtiz-Muñoz, Luis
dc.contributor.authorOlguín, Pablo
dc.contributor.authorRada, Gabriel
dc.contributor.authorMadrid, Eva
dc.date.accessioned2022-11-30T02:46:35Z
dc.date.available2022-11-30T02:46:35Z
dc.date.issued2021
dc.description.abstractObjective: This living systematic review aims to provide a timely, rigorous, and continuously updated summary of the evidence available on the role of angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB) in the treatment of patients with COVID-19. Data sources: We conducted searches in PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), grey literature and in a centralized repository in L·OVE (Living OVerview of Evidence), which retrieves articles from multiple sources such as PubMed/MEDLINE, Cochrane Central Register of Controlled Trials, Embase, among other pre-print and protocols repositories. In response to the COVID-19 emergency, L·OVE (Living OVerview of Evidence) was adapted to expand the range of evidence and customized to group all COVID-19 evidence in one place on a daily search basis. The search covered a period of time up to July 31, 2020. Eligibility criteria for selecting studies and methods: We adapted an already published standard protocol for multiple parallel living systematic reviews to this question's specificities. We included randomized trials evaluating the effect of either suspension or indication of angiotensin-converting-enzyme inhibitors or angiotensin II receptor blockers as monotherapy, or in combination versus placebo or no treatment in patients with COVID-19.We searched for randomized trials evaluating the effect of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers versus placebo or no treatment in patients with COVID-19. Two reviewers independently screened each study for eligibility, extracted data, and assessed the risk of bias. We pooled the results using meta-analysis and applied the GRADE system to assess the certainty of the evidence for each outcome. We will resubmit results every time the conclusions change or whenever there are substantial updates. Results: We screened 772 records, but none was considered for eligibility. We identified 55 ongoing studies, including 41 randomized trials evaluating angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for patients with COVID-19. Conclusions: We did not find a randomized clinical trial meeting our inclusion criteria, and hence there is no evidence for supporting the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in the treatment of patients with COVID-19. A substantial number of ongoing studies would provide valuable evidence to inform researchers and decision-makers in the near future.en_ES
dc.facultadFacultad de Medicinaen_ES
dc.file.nameMeza_Angi2021.pdf
dc.identifier.citationMeza N, Pérez-Bracchiglione J, Pérez I, Carvajal C, Ortiz-Muñoz L, Olguín P, Rada G, Madrid E. Angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers for COVID-19: A living systematic review of randomized clinical trials. Medwave 2020;21(2):e8105en_ES
dc.identifier.doi10.5867/medwave.2021.02.8105
dc.identifier.urihttp://repositoriobibliotecas.uv.cl/handle/uvscl/7427
dc.languageen
dc.publisherMedwave
dc.rightsbajo una licencia Creative Commons Atribución-No Comercial 3.0 Unported. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.
dc.sourceMedwave
dc.subjectCOVID-19en_ES
dc.subjectSEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2en_ES
dc.subjectCORONAVIRUS INFECTIONSen_ES
dc.subjectSYSTEMATIC REVIEWen_ES
dc.titleAngiotensin-converting-enzyme inhibitors and angiotensin II re-ceptor blockers for COVID-19: A living systematic review of randomized clinical trials
dc.typeArticulo
uv.departamentoCentro Interdisciplinario de Estudios en Salud (CIESAL)

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Meza_Angi2021.pdf
Tamaño:
338.59 KB
Formato:
Adobe Portable Document Format
Descargar

Colecciones

Artículos investigadores UV